SCHEMBL7216635

SCHEMBL7216635

CCCOc1ccc(Oc2ccc3c(c2)C=C(C(=O)OC)CCS3(=O)=O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.39
MAPK1 P28482 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ACACA Q13085 8/20 0.36
ACACB O00763 8/20 0.36
MAPT P10636 1/20 0.36
PLK1 P53350 1/20 0.36
TSHR P16473 2/20 0.35
PLA2G2A P14555 1/20 0.35
CA12 O43570 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
THRB P10828 1/20 0.34
HPGD P15428 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7216131 0.94 MAPT (0.36) LTA4HMAPK1SMN1; SMN2ACACAACACB
SCHEMBL7221094 0.93 ACACB (0.42) SMN1; SMN2ACACAACACBMAPTKDM4E
SCHEMBL7934085 0.90 PLA2G2A (0.39) MAPK1SMN1; SMN2ACACAACACBMAPT
SCHEMBL7218340 0.89 LTA4H (0.40) LTA4HMAPK1SMN1; SMN2ACACAACACB
SCHEMBL7221547 0.88 LMNA (0.40) MAPK1SMN1; SMN2ACACBMAPTALDH1A1
SCHEMBL7218022 0.88 ACACB (0.38) MAPK1ACACAACACBMAPTTSHR
SCHEMBL7215982 0.88 ACACB (0.36) SMN1; SMN2ACACAACACBMAPTCA12
SCHEMBL7928473 0.85 ALPL (0.43) MAPTPLA2G2AGAAALPL
SCHEMBL7216023 0.84 L3MBTL1 (0.34) SMN1; SMN2MAPTTSHRCA12CA2
SCHEMBL7975157 0.84 RARB (0.40) MAPTPLA2G2AKDM4EALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627651-B1 Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-30 US disclosed
EP-1182195-A1 CYCLIC COMPOUNDS AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-02-27 EP disclosed